The stock of QLT Inc. (TSE:QLT) is a huge mover today! About 12,900 shares traded hands or 219.31% up from the average. QLT Inc. (TSE:QLT) has declined 14.45% since April 1, 2016 and is downtrending. It has underperformed by 16.41% the S&P500.
The move comes after 9 months positive chart setup for the $117.31M company. It was reported on Nov, 8 by Barchart.com. We have $5.27 PT which if reached, will make TSE:QLT worth $153.68 million more.
More notable recent QLT Inc. (TSE:QLT) news were published by: Streetinsider.com which released: “QLT, Inc. (QLTI) Shareholders Approve Aegerion Pharmaceuticals Merger” on November 08, 2016, also Streetinsider.com with their article: “QLT Inc. (QLTI), Aegerion Pharma (AEGR) Enter Strategic Merger Agreement” published on June 15, 2016, Streetinsider.com published: “QLT, Inc. (QLTI) Acquires Shares of Aralez Pharmaceuticals (ARLZ), Announces …” on February 05, 2016. More interesting news about QLT Inc. (TSE:QLT) were released by: Reuters.com and their article: “BRIEF-Aegerion pharmaceuticals, Qlt Inc agree to strategic merger” published on June 15, 2016 as well as Globenewswire.com‘s news article titled: “QLT Inc. Completes Enrollment in its Natural History Study” with publication date: April 22, 2016.
QLT Inc. is a biotechnology company
QLT.TO Company Profile
QLT Inc., incorporated in 1981, is a biotechnology company. The Firm is focused on the development and commercialization of ocular products that address the unmet medical needs of patients and clinicians around the world. The Company’s activities consist of clinical development programs focused on its synthetic retinoid, QLT091001, for the treatment of certain age-related and inherited retinal diseases (IRD) caused by retinal pigment epithelium protein 65 (RPE65) and lecithin: retinol acyltransferase (LRAT) gene mutations. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a biochemical component of the visual retinoid cycle.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.